Evidence map›Paper›PMID 40828784›Full record

ReviewAmerican journal of physiology. Renal physiology2025

Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease.

Eleni Hughes, Xiaoxin X Wang, Lily Sabol, Keely Barton, Sujit Hegde, Komuraiah Myakala, Ewa Krawczyk, Avi Rosenberg, Moshe Levi

Abstract readReview
In one paragraph

Review in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Frontiers in pharmacology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Metabolic Crosstalk in Diabetic Kidney Disease: Synergistic Effects of Glucotoxicity and Lipotoxicity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eleni HughesDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.
Xiaoxin X WangDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.ORCID 0000-0001-9205-6228
Lily SabolDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.ORCID 0000-0001-8463-8308
Keely BartonDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.
Sujit HegdeDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.
Komuraiah MyakalaDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.ORCID 0000-0003-3233-047X
Ewa KrawczykDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, District of Columbia, United States.ORCID 0000-0002-1394-9720
Avi RosenbergRenal Pathology Service, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.ORCID 0000-0003-2356-950X
Moshe LeviDepartment of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia, United States.ORCID 0000-0001-6403-2261

Funding

Treatment of kidney disease in diabetesR01DK116567 · NIDDK · GEORGETOWN UNIVERSITY · PI LEVI, MOSHE · 2018 to 2021
$1.8M
Role of Glycosphingolipids in Kidney Disease in Diabetes and ObesityR01DK139676 · NIDDK · GEORGETOWN UNIVERSITY · PI MOSHE LEVI · 2025 to 2026
$1.7M
Treatment of Kidney Disease in Diabetes and ObesityR01DK098336 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LEVI, MOSHE · 2013 to 2016
$1.3M
Renal Lipid Metabolism in Diabetic NephropathyR01DK062209 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LEVI, MOSHE · 2003 to 2006
$922k
HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) 139676NIDDK NIH HHS R01 DK062209NIDDK NIH HHS R01 DK098336NIDDK NIH HHS R01 DK116567NIDDK NIH HHS R01 DK139676
6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD) and remains a significant clinical challenge due to its complex pathogenesis. This review explores the intricate interplay of metabolic, inflammatory, and cellular mechanisms that drive DKD progression, with a particular focus on lipid metabolism, mitochondrial dysfunction, oxidative stress, inflammation, cell injury, and epigenetic modifications. Advances in histopathological and molecular studies have expanded our understanding of glomerular, tubular, and vascular abnormalities in DKD, highlighting the critical role of nuclear hormone receptors, transcription factors, and G protein-coupled receptors in regulating renal lipid accumulation, mitochondrial function, inflammation, oxidative stress, and fibrotic pathways. In addition, emerging evidence implicates novel cell death mechanisms, including ferroptosis, necroptosis, pyroptosis, and PANoptosis, in DKD pathology. Epigenetic modifications, including DNA methylation, histone modifications, and noncoding RNAs, further contribute to disease progression by regulating gene expression in response to metabolic stress. As current therapeutic strategies remain insufficient to prevent DKD progression, this review also discusses novel molecular targets and emerging therapeutic approaches aimed at mitigating lipid toxicity, enhancing mitochondrial function, and suppressing inflammation. By integrating insights from histopathology, molecular biology, and translational research, this review provides a comprehensive framework for developing future strategies to delay or prevent DKD progression.

Indexed as

Diabetic NephropathiesKidneyLipid MetabolismMitochondriaReceptors, Cytoplasmic and NuclearAnimalsEpigenesis, GeneticHumansOxidative StressSignal TransductionReceptors, Cytoplasmic and Nucleardiabetic kidney diseaseinflammationlipidsmitochondrianuclear receptors

Identifiers

PMID40828784
PMCPMC13179837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.